Company intelligence / Profile preview
Allarity Therapeutics
Boston, Massachusetts, United Statesallarity.com ↗
- Ownership
- Public · ALLR
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Ongoing Phase 2 clinical trial for stenoparib in advanced ovarian cancer showing promising results, with two patients exceeding 14 months on treatment. In early Phase 2 data from December 2023, one patient experienced a complete response and four had stable disease, with all five patients experiencing clinical benefit exceeding 20 weeks.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Financials
- Market cap
- $15.5M
- Total revenue
- $320K
- Enterprise value
- $20.8M
Beyond the preview
Go deeper on Allarity Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allarity Therapeutics.